Immunotherapy, thymalfasin, and chemo before surgery for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage III stomach or gastroesophageal junction cancer (HER2-negative) that can be removed with surgery.
- You have not had any prior chemotherapy, radiation, or immunotherapy for this cancer.
- You are in good overall health with normal organ function (kidney, liver, bone marrow) and can tolerate surgery.
- You are willing to use contraception (if applicable) and avoid pregnancy for several months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of three drugs (envollizumab, fruquintinib, and chemotherapy) given before surgery, to see if it can shrink stomach cancer enough to make it removable. It compares this combination to chemotherapy alone.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a new combination of an immunotherapy drug (cadonilimab) with chemotherapy before surgery for stomach cancer. The goal is to see if this approach shrinks tumors more effectively and improves outcomes.
This trial tests whether adding an immunotherapy drug called sintilimab to chemotherapy and radiation before surgery can help shrink tumors and improve outcomes for people with gastroesophageal junction cancer. It is designed for patients who have not had previous treatment for this cancer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.